RXDX Stock: $35 Price Target By Oppenheimer

By Amit Chowdhry ● Oct 7, 2021
  • The shares of Prometheus Biosciences Inc (NASDAQ: RXDX) have received a $35 price target by Oppenheimer. These are the details.

The shares of Prometheus Biosciences Inc (NASDAQ: RXDX) have received a $35 price target by Oppenheimer. And Oppenheimer analyst Jeff Jones had initiated coverage of Prometheus Biosciences with an “Outperform” rating.

Jones noted that Prometheus is representing the leading edge of precision medicine for gastrointestinal and autoimmune disorders. And the company’s lead candidate PRA023 is currently in Phase 2 studies for ulcerative colitis and Crohn’s disease with results for both anticipated late 2022.

Plus Jones is bullish on Prometheus and sees the upcoming announcement of plans for a new indication for PRA023 as a near-term catalyst.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.